PACRG-AS2: A Non-Coding RNA Molecule as a Potential Drug Target or Biomarker for Cancer

Target Name: PACRG-AS2

NCBI ID: G101929239

PACRG-AS2

Other Name(s): PACRG antisense RNA 2, transcript variant 1 | PACRG antisense RNA 2

PACRG-AS2: A Non-Coding RNA Molecule as a Potential Drug Target or Biomarker for Cancer

PACRG-AS2 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule is derived from the gene ATGCTAGGG and has a length of 20 nucleotides. It is expressed in various tissues and cells of the body and is known to play a role in cell signaling pathways.

PACRG-AS2 function

PACRG-AS2 is involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation. It is a non-coding RNA molecule that can interact with various protein molecules, including transcription factors, to regulate their activity and ensure the expression of specific genes.

One of the known functions of PACRG-AS2 is its role in cell apoptosis. Apoptosis is a natural process that helps remove damaged or dysfunctional cells from the body, and it is regulated by various factors, including the balance between pro- and anti-apoptotic factors. PACRG-AS2 has been shown to play a role in the regulation of apoptosis by promoting the expression of genes that are involved in cell survival and by inhibiting the expression of genes that are involved in cell death.

Another function of PACRG-AS2 is its role in cell signaling pathways. PACRG-AS2 has been shown to interact with various signaling molecules, including NF-kappa1, to regulate cellular processes such as cell growth, differentiation, and inflammation.

PACRG-AS2 as a drug target

PACRG-AS2 has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule has been shown to play a role in the regulation of cellular processes that are involved in cancer development, including the regulation of cell apoptosis, cell proliferation, and angiogenesis.

One of the potential mechanisms by which PACRG-AS2 can contribute to cancer development is its role in cell apoptosis. Cancer cells often have an increased ability to survive and divide than normal cells, and this ability is often associated with an increased risk of apoptosis. PACRG-AS2 has been shown to play a role in the regulation of cell apoptosis by promoting the expression of genes that are involved in cell survival and by inhibiting the expression of genes that are involved in cell death.

Another potential mechanism by which PACRG-AS2 can contribute to cancer development is its role in cell proliferation. Cancer cells often have an increased ability to divide than normal cells, and this ability is often associated with an increased risk of cancer progression. PACRG-AS2 has been shown to play a role in the regulation of cell proliferation by promoting the expression of genes that are involved in cell growth and by inhibiting the expression of genes that are involved in cell division.

In addition to its role in cell apoptosis and proliferation, PACRG-AS2 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. Angiogenesis is a critical process for the development and maintenance of various tissues, including the brain and the immune system.

Conclusion

PACRG-AS2 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule is involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation. It is also known to play a role in cell signaling pathways and has been shown to contribute to the regulation of cell apoptosis, cell proliferation, and angiogenesis. Further research is needed to fully understand the role of PACRG-AS2 in

Protein Name: PACRG Antisense RNA 2

The "PACRG-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PACRG-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets